Pancreatic Cancer Clinical Trials in Cleveland

Showing 101-120 of 158 trials

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

NCT00493441

The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.

Pancreatic Cancer

Vertex Pharmaceuticals Incorporated28 participantsStarted Jun 2007

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +13 more locations

COMPLETEDPhase 2< 1 mile

Vaccine Study for Surgically Resected Pancreatic Cancer

NCT00569387

To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.

Pancreatic Cancer

NewLink Genetics Corporation73 participantsStarted Dec 2007

Scottsdale, Arizona, United States • Los Angeles, California, United States • Orange, California, United States +15 more locations

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Other Conditions in Cleveland